Table 1.

Summary of various caged protein systems, both viral and non-viral, which have been explored as delivery vehicles for therapeutics. The specific caged protein, drugs used, and the phase of research are given.

Protein cage	Drug	Phase of Recent Investigations	References
Virus-like particle
Adenovirus	bleomycin	in vitro	[26]
	paclitaxel	in vivo	[**22]
Avian sarcoma leukosis virus	Cre recombinase	in vitro	[**19]
	5-FU
	Caspace-8
	Ifn-γ
	TRAIL
Cowpea chlorotic mottle virus	Ru(bpy2)phen-IA	in vitro	[58]
Cowpea mosaic virus	DOX	in vitro	[11]
	proflavin		[*34]
Cucumber mosaic virus	DOX	in vivo	[*35]
Hepatitis B virus	CCL19	in vivo	[18]
	IL-2
	CpG		[31]
	siRNA		[55]
Hibiscus ringspot virus	DOX	in vitro	[38]
HIV-1	CD40L	in vivo	[16]
JC polyomavirus	paclitaxel	in vitro	[45]
	siRNA	in vivo	[47]
MS2 Bacteriophage	siRNA	in vitro	[**40,41,55]
	DOX		[**40]
	5-fluorouracil
	ricin toxin A-chain
	miRNA	in vivo	[42,43]
	antisense ssDNA		[44]
Murine polyomavirus	methotrexate	in vitro	[24]
Qβ	EGF	in vitro	[68]
	porphyrin		[*21]
	CpG	phase 2 clinical trial	[*67]
Red clover necrotic mosaic virus	DOX	in vitro	[46]
Rotavirus	DOX	in vitro	[25]
SHIV	CD40L	in vivo	[20]
Non-viral particle
E2 subunit of pyruvate dehydrogenase	DOX	in vitro	[10,57]
	CpG		[*65]
Ferritin	duanomycin	in vitro	[37]
	cisplatin		[32]
	5-fluorouracil		[36]
	trastuzumab		[69]
	AP-1 peptide	in vivo	[17]
	DOX		[*39]
DNA binding protein	SnCe6	in vitro	[23]
Heat shock protein	DOX	in vitro	[27,28]